Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
76.93
-1.23 (-1.57%)
Aug 12, 2025, 4:00 PM - Market closed
Inozyme Pharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 4,148 | 4,175 | 1,402 | 1,522 | 1,503 | 823.4 | Upgrade |
Depreciation & Amortization | 151.8 | 155.2 | 144.9 | 139.6 | 134.8 | 107.2 | Upgrade |
Loss (Gain) From Sale of Assets | -3,348 | -3,348 | - | - | - | - | Upgrade |
Asset Writedown & Restructuring Costs | 47.1 | - | - | 55.1 | 4 | - | Upgrade |
Loss (Gain) From Sale of Investments | -5.2 | -5.2 | 0.1 | 51.5 | -36.8 | -21.2 | Upgrade |
Stock-Based Compensation | 151.5 | 162.3 | 139.4 | 126.8 | 109.3 | 92.6 | Upgrade |
Other Operating Activities | -277.8 | -337.1 | -264.7 | -255.3 | -127.6 | 10.1 | Upgrade |
Change in Accounts Receivable | 84.6 | 121.2 | -141.2 | -84.1 | -91.1 | 41.9 | Upgrade |
Change in Inventory | -50.9 | -256.1 | -289 | -213.4 | 19 | -120.6 | Upgrade |
Change in Accounts Payable | 27.1 | 89.5 | 146 | -21.4 | 195.2 | -84.5 | Upgrade |
Change in Income Taxes | -5.9 | -186.7 | -5.8 | -5.6 | 62 | -52.9 | Upgrade |
Change in Other Net Operating Assets | -126.8 | -27.2 | -236.3 | -96.9 | -39.8 | 258.3 | Upgrade |
Operating Cash Flow | 794.9 | 542.3 | 895.8 | 1,218 | 1,732 | 1,054 | Upgrade |
Operating Cash Flow Growth | -8.22% | -39.46% | -26.46% | -29.67% | 64.29% | -10.87% | Upgrade |
Capital Expenditures | -207 | -252.4 | -253 | -244.6 | -325.8 | -407 | Upgrade |
Cash Acquisitions | -1,062 | -1,062 | -95.2 | - | - | - | Upgrade |
Divestitures | 3,927 | 3,927 | - | - | - | - | Upgrade |
Sale (Purchase) of Intangibles | -10 | -30 | -13.3 | -20.2 | -4 | -0.3 | Upgrade |
Investment in Securities | -334.1 | -88.2 | 640.3 | 689.8 | -1,350 | -74.7 | Upgrade |
Other Investing Activities | -276.3 | -182.1 | -105 | -172.7 | -42.6 | -49.1 | Upgrade |
Investing Cash Flow | 2,038 | 2,313 | 173.8 | 252.3 | -1,723 | -531.1 | Upgrade |
Long-Term Debt Issued | - | - | - | - | 5.2 | 16.2 | Upgrade |
Long-Term Debt Repaid | - | - | - | - | -7 | -17 | Upgrade |
Net Debt Issued (Repaid) | - | - | - | - | -1.8 | -0.8 | Upgrade |
Issuance of Common Stock | 170.2 | 179.5 | 169.9 | 146.4 | 158.6 | 140.5 | Upgrade |
Repurchase of Common Stock | -1,265 | -1,159 | -879.6 | -1,727 | -512.8 | -625.4 | Upgrade |
Other Financing Activities | -58.4 | -3.1 | -1.3 | -3.8 | -0.3 | -1.2 | Upgrade |
Financing Cash Flow | -1,153 | -983 | -711 | -1,585 | -356.3 | -486.9 | Upgrade |
Foreign Exchange Rate Adjustments | -47.8 | 38.6 | 16.8 | 19.2 | 13.9 | -20.5 | Upgrade |
Net Cash Flow | 1,632 | 1,911 | 375.4 | -94.8 | -332.8 | 15.8 | Upgrade |
Free Cash Flow | 587.9 | 289.9 | 642.8 | 973.6 | 1,406 | 647.3 | Upgrade |
Free Cash Flow Growth | 2.82% | -54.90% | -33.98% | -30.77% | 117.26% | -30.29% | Upgrade |
Free Cash Flow Margin | 10.34% | 5.33% | 12.83% | 21.81% | 26.88% | 14.76% | Upgrade |
Free Cash Flow Per Share | 0.99 | 0.48 | 1.05 | 1.56 | 2.23 | 1.02 | Upgrade |
Cash Interest Paid | 19.6 | 19.6 | 19.9 | 19.3 | 20.2 | 19.9 | Upgrade |
Cash Income Tax Paid | 1,013 | 1,166 | 444.9 | 466.7 | 182.5 | 197.9 | Upgrade |
Levered Free Cash Flow | 1,262 | 1,351 | 589.83 | 776.73 | 1,009 | 373.75 | Upgrade |
Unlevered Free Cash Flow | 1,274 | 1,363 | 600.83 | 788.73 | 1,020 | 383.63 | Upgrade |
Change in Working Capital | -71.9 | -259.3 | -526.3 | -421.4 | 145.3 | 42.2 | Upgrade |
Updated Jul 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.